Stock Analiz

Evolus, Inc. EOLS

Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026

$6.96Market cap $461M
Open the interactive analysis →

Evolus, Inc. (EOLS) is a healthcare company listed in the US with a market value of about $461M. In the twelve months to September 30, 2026 it had revenue of $325M and net income of -$31M, a net margin of -9.6%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 39% a year, a 5-year average ROIC of -31%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 64% below the current price.

About Evolus

Evolus is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $35M in 2019 to $297M in 2025, growth of about 42.9% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 15% over three years (dilution for shareholders). It spends 3% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record2/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 5-year revenue growth above 8% a year
  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E38.4
P/FCF—
P/S1.4
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-1.1%
Shareholder yield0.0%
Intrinsic value vs. price−64%

Growth and quality

Revenue growth (1 yr)11.6%
Revenue growth (5 yrs, per year)39.4%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-32.8%
ROIC (5-yr avg.)-30.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$325M$297M$266M$202M$149M$100M$57M$35M$0—
Net income-$31M-$52M-$50M-$62M-$74M-$47M-$163M-$90M-$47M-$4M
Free cash flow-$5M-$46M-$19M-$34M-$87M-$34M-$59M-$94M-$26M-$13M
EPS (diluted)$-0.47$-0.80$-0.81$-1.08$-1.33$-0.94$-4.83$-3.19$-1.92$-0.27
Net margin-9.6%-17.4%-18.9%-30.5%-50.1%-47.0%-288.3%-257.8%——
ROIC—-19.6%-20.1%-36.7%-55.5%-22.4%—-53.6%-43.2%-14.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $15.40, 121% above the current price; targets range from $12.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-0.03 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Evolus stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 64% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Evolus pay a dividend?

Not currently.

Is Evolus a good stock to buy?

We do not give buy or sell advice. Evolus scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.